Prometheus Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Prometheus Biosciences generated cash of -$63,505,000, which is more than the previous year. Cash used in financing activities reached the amount of $267,694,000 last year. Net change in cash is therefore $203,053,000.
Cash Flow
| 2014 | -32.48M | -74.32M | -11.22M |
|---|---|---|---|
| 2016 | -90.11M | 14.26M | 36.27M |
| 2021 | -63.50M | -1.13M | 267.69M |
RXDX Cash Flow Statement (2015 – 2022)
| 2022 | 2017 | 2015 | |
|---|---|---|---|
Cash at beginning of period | 54.20M | 46.38M | 51.80M |
Operating activities | |||
Net income | -90.19M | -103.63M | -39.98M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 258K | 3.47M | 527.67K |
Stock-based compensation expense | 10.69M | 7.72M | 2.28M |
| Deferred income tax benefit | 10.69M | 7.72M | 2.28M |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | 7K | 0 | 0 |
Inventories | -3.34M | 0 | 0 |
Accounts payable | 103K | 95K | 163.66K |
Cash generated by operating activities | -63.50M | -90.11M | -32.48M |
Investing activities | |||
Purchases Of Investments | 0 | -123.85M | -89.28M |
Investments In Property Plant And Equipment | -1.13M | -2.45M | -3.11M |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -1.13M | 14.26M | -74.32M |
Financing activities | |||
Common Stock Issued | 218.5M | 53.89M | 0 |
Payments for dividends | -428K | 0 | 0 |
Repurchases of common stock | 428K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 |
Cash used in financing activities | 267.69M | 36.27M | -11.22M |
Net Change In Cash | 203.05M | -22.04M | -45.45M |
Cash at end of period | 257.25M | 24.34M | 6.34M |
| Data source | Data source | Data source |